Fairvalue-Calculator Fairvalue-Calculator
EN DE

Asahi Intecc Co (AHICF) Fair Value & Analysis

Healthcare · US · Market cap $5.7B

Price$21.41
Fair Value$9.53
Upside-55.5%
Quality95/100
Evidence: High Range $7.00 – $12.05

Analysis

Asahi Intecc Co (AHICF) currently trades at $21.41, while our model-based Fair Value estimate is $9.53 — implying the stock looks roughly 55.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Asahi Intecc Co., Ltd. engages in the development, manufacture, and sale of medical devices in Japan, the United States, Europe, China, and internationally. The company operates through the Medical and Device segments. It provides percutaneous coronary intervention (PCI) guide wires, guiding catheters, balloon catheters, and penetration catheters for cardiology; peripheral guide wires, IVR guide wires, micro catheters, and cerebrovascular system guide wires for peripheral vascular, abdominal vascular, and cerebrovascular systems; and catheters for angiography. The company also offers OEM ODM service services for medical devices; and medical and industrial components, such as wire rope, coils, coatings, tubes, terminal processing products, synchronous round belt, and flexible shaft. In addition, it develops, manufactures, and sells ultra-fine stainless steel wire ropes. The company was formerly known as Asahi Mini Rope Sales Co., Ltd. and changed its name to Asahi Intecc Co., Ltd. in…

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.